Patrick joined Aescap at its start in 2005. Where Aescap initially invested in private life sciences companies, Patrick has been a private investor in public equity for over 30 years. His track record as a private investor in public biotech companies over the 2-year run-in period before starting Aescap 2.0 in 2016 is 133% (cumulative over 2014+2015), outperforming the Nasdaq Biotech Index over 2,5x. From 1995 to 2004 Patrick was the managing director of Firm United Healthcare B.V., a company that provided market research, strategy and communication consultancy services. As a co-founder of Firm United Healthcare Patrick was responsible for growing the company into a market leader on the European continent and guided over 35 listed pharma and biotech companies to successfully introduce or grow their products. He currently applies his expertise to successfully select and guide Aescap’s investments in the private and public biotech sector. During this period, he also co-founded Interactive Healthcare and the Healthcare Management School. In 2004/2005 he sold his share in all three companies.
Since then he has gained professional experience as both an investor as well as on board level, with private as well as public life sciences companies such as Aquapharm Biodiscovery Ltd, Cassini B.V., Easyscan B.V., F-star Ltd, Orphazyme Aps, and Shire International Licensing B.V.. In 2003, he became a visiting teacher of the business school of the University of Wageningen on ‘Strategy in the Pharmaceutical Industry’. He published several articles on biopharma marketing strategy and has been a speaker and moderator at many healthcare seminars and congresses. Patrick studied physical therapy followed by business economics with a specialization in entrepreneurship. Later in his career he completed an MBA in Executive Management and Consultancy from LMS.
Maurits Brandt holds a Master’s in Life Science and Business Development from Leiden University and a Bachelor’s in Biochemistry from Leiden University and TU Delft. During his master he specialized in the field of medical oncology and focused on the business aspects of exploiting emerging technologies. He performed his research on the Technische Universität Berlin. During this time, he started to learn about the aspects of long term investing in life sciences companies. Maurits joined Aescap 2.0 as an analyst in 2016.
Paolo Del Bufalo obtained a Bachelor’s degree in Chemistry at La Sapienza University of Rome after which he completed two Master tracks at Leiden University, one in Chemical Biology Research and one in Science Based Business. Throughout his academic research career he focused on supramolecular chemistry and photochemistry for applications in medicinal chemistry. During his business studies, he acquired knowledge to combine his scientific background with the business environment, particularly with value investing. Paolo joined Aescap 2.0 as an analyst in 2018.
Michiel de Haan has been active in life sciences since 1987 when he spun-out Atlas Venture from the ING bank. Under his leadership Atlas developed into a European-American venture capital firm with offices in Amsterdam, Munich, Boston and London and invested in over 300 venture backed companies in Information Technology and Life Sciences. Michiel has been active on numerous boards of Life Science companies such as Crucell and Morphosys.
Michiel is past chairman of the European Venture Capital Association (EVCA) and co-founder of the European Venture Philanthropy Association (EVPA). In 1974 Michiel received an MBA from Erasmus University in Rotterdam. From 1974 until 1980 he worked at NMB (now ING). He started NMB-Participatie, which he later bought to create Atlas Venture. Currently he is General Partner of Aescap Venture that he co-founded together with Dinko Valerio in 2005 and is a fund advisor to Aescap 2.0.
Bo Jesper Hansen, M.D., Ph.D. resigned as the Executive Chairman of the Board of SOBI AB (Swedish Orphan Biovitrum AB) in 2016. SOBI is a biotech company listed on the Swedish stock exchange and at the time had a market capitalization of around 3,5 billion euros. He is Chairman of Karolinska Development AB and is also non-executive Director of the biotech company Orphazyme ApS. Dr Hansen served as CEO and President to the Board of Swedish Orphan International (1998-2010) until the merger with Biovitrum, forming Swedish Orphan Biovitrum. He then became the company’s executive chairman. He also was non-executive Director of Gambro until its acquisition by Baxter, as well as of Zymenex, until its acquisition by Chiesi. Dr. Hansen was the Executive Chairman of Ablynx until its acquisition by Sanofi, as well as of Topotarget and in this role led the merger with BioAlliance forming OnXeo. He founded Scandinavian Medical Research during which he served as Medical Advisor for the multinationals Synthélabo, Pfizer, Pharmacia and Yamanouchi Pharmaceutical. He has also been a board member with the companies TopoTarget A/S, CMC AB, MipSalus Aps, Kontrast AB, Hyperion Therapeutics, Inc. Newron Pharmaceuticals S.p.A, Novagali Pharma S.A. and VivolutionA/S.
Dr Hansen has an extensive knowledge within clinical study design, regulatory, pharmacovigilance, and business development. He has an M.D. in Urology and a PhD from the University of Copenhagen. Mr Krol and Mr Hansen first met in 2012 as members of the supervisory board of biotech company Orphazyme S.p.A.
Fred Oudshoorn is the founder and managing director of Jonghoud BV, an investment firm in amongst others, equity of private and listed healthcare companies. As a pharmacist he built a chain of 40 pharmacies “De Vier Vijzels” which was later acquired by Alliance Unichem. He is also a founder of MediZorg, the former chairman of Sinensis Laboratoria and supervisory board member of Kadans and Kadans Science Partners. Mr Krol and Mr Oudshoorn first met in their function as supervisory board members back in 2012 and soon discovered their mutual activities in investing in public innovative medical companies.
Gert Hoogland, M.D., MBA (INSEAD) is a pharmaceutical executive with deep operational experience. He began his career in 1982 as Medical Advisor to Organon NV in Oss, The Netherlands, followed by CEO positions for Schering AG in New Zealand and South Africa. He then founded Pharmaplan Pty Ltd in Johannesburg, which became the leading specialty pharma distributor in Africa representing biotech companies like Biogen, Bracco, Recordati, Ipsen, Genzyme and Shire. After the sale of this company to the Canadian Specialty Pharma company Paladin Inc. he relocated to Zurich to start HealthCrest AG, a healthcare investment and consulting company. Hoogland has initiated investments in many private and public healthcare companies, geographically encompassing Europe, India, China, the US and Africa and continues to serve on the Board of many of these portfolio companies. Mr Krol and Mr Hoogland first met in 2013 as investors in i-Optics BV.